BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 10946886)

  • 1. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa.
    Gianotti L; Pincelli AI; Scacchi M; Rolla M; Bellitti D; Arvat E; Lanfranco F; Torsello A; Ghigo E; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2805-9. PubMed ID: 10946886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
    Broglio F; Gianotti L; Destefanis S; Fassino S; Abbate Daga G; Mondelli V; Lanfranco F; Gottero C; Gauna C; Hofland L; Van der Lely AJ; Ghigo E
    Clin Endocrinol (Oxf); 2004 May; 60(5):592-9. PubMed ID: 15104562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism.
    Veldhuis JD; Keenan DM; Bailey JN; Miles JM; Bowers CY
    Eur J Endocrinol; 2009 Aug; 161(2):293-300. PubMed ID: 19458139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
    Gianotti L; Arvat E; Valetto MR; Ramunni J; Di Vito L; Maccagno B; Camanni F; Ghigo E
    Biol Psychiatry; 1998 Feb; 43(3):181-7. PubMed ID: 9494699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men.
    Veldhuis JD; Weltman JY; Weltman AL; Iranmanesh A; Muller EE; Bowers CY
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5542-8. PubMed ID: 15531509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L; Rolla M; Arvat E; Belliti D; Valetto MR; Ferdeghini M; Ghigo E; Müller EE
    Biol Psychiatry; 1999 Feb; 45(3):334-9. PubMed ID: 10023511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM; Hartman ML; Pieper KS; Skiles EH; Pezzoli SS; Hintz RL; Thorner MO
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels.
    Cano A; Castelo-Branco C; Tarín JJ
    Fertil Steril; 1999 Feb; 71(2):261-7. PubMed ID: 9988395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
    Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
    Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor I.
    Wilson ME
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2018-28. PubMed ID: 9626134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency.
    Maccario M; Aimaretti G; Grottoli S; Gauna C; Tassone F; Corneli G; Rossetto R; Wu Z; Strasburger CJ; Ghigo E
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1233-9. PubMed ID: 11477509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea.
    Laughlin GA; Dominguez CE; Yen SS
    J Clin Endocrinol Metab; 1998 Jan; 83(1):25-32. PubMed ID: 9435412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbances in the growth hormone-insulin-like growth factor axis in children and adolescents with different eating disorders.
    Argente J; Caballo N; Barrios V; Muñoz MT; Pozo J; Chowen JA; Hernández M
    Horm Res; 1997; 48 Suppl 4():16-8. PubMed ID: 9350440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness.
    Gianotti L; Broglio F; Ramunni J; Lanfranco F; Gauna C; Benso A; Zanello M; Arvat E; Ghigo E
    Eat Weight Disord; 1998 Jun; 3(2):64-70. PubMed ID: 10728152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.